Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene-based screen sorts cancer cases, say Stanford researchers

29.04.2004


Six genes may hold the answer to whether a person’s lymphoma is likely to respond to treatment. This finding by researchers at Stanford University School of Medicine could result in the first gene-based screen to identify people who need the most aggressive therapy.



When a person is diagnosed with diffuse large-B-cell lymphoma, doctors use a group of indicators called the International Prognostic Index, or IPI, which includes a person’s age, tumor stage and blood markers to decide how to treat the cancer. Those with the highest IPI scores get the most aggressive therapy. However, two people with the same score may still react differently to treatment. One thought has been that a genetic screen may fine-tune the distinction between the most aggressive and least aggressive cancers.

"It makes a big difference in your treatment decisions if you think you have a high chance of success or if you don’t," said Ronald Levy, MD, the Robert K. and Helen K. Summy Professor, who led the study. He said if doctors know a patient isn’t likely to respond well to standard therapy, the patient may be a candidate for novel therapies undergoing clinical trials.


"New therapies are usually tested in people who have failed the standard therapy," Levy said. "If you know in advance who won’t respond well, you can treat them more aggressively or include these patients in trials of the many promising, new targeted therapies."

Over the past five years groups of researchers have used microarrays, which take a snapshot of which genes are active in different tissues, to find large groups of genes that predict a person’s survival. These studies have resulted in huge lists of mostly non-overlapping genes. Not only are there too many genes to be screened by most medical labs, the research groups haven’t agreed on which genes should be part of those screens.

Levy and his colleagues narrowed the list of potentially informative genes down to the 36 most likely candidates. They then analyzed how active those genes were in 66 tumor samples from people with diffuse large-B-cell lymphoma who had been treated at Stanford. The results of this work are published in the April 29 issue of the New England Journal of Medicine.

On its own, none of the genes predicted how long a patient lived after treatment. But six of the genes taken together could predict how long the 66 patients survived. Researchers then tested the predictive power of those six genes in patients who participated in two previous microarray studies. In this combined group of 298 patients the six genes once again distinguished between patients who responded well to treatment and those who did not.

Rather than using microarray technology to analyze the genes’ activity, Levy and his colleagues worked with scientists at Applied Biosystems Inc. to develop a screen using a technique called RT-PCR. This approach would be easier for medical labs, which already use RT-PCR for other disease tests. Levy said although microarrays and RT-PCR give similar information, the new test is more likely to become widely used if it is easy to incorporate into existing medical labs. "You want to introduce something that helps people do what they are doing now - but better," he said.

He added that the group still needs to check how well the six genes discriminate between good and bad responders in additional groups of patients, especially those who are receiving therapies that weren’t available when the original patients were treated. If the test can still predict those who need the most aggressive treatment, the researchers will move forward with making the screen widely available. He said doctors would likely combine information from the IPI clinical index with results from the six-gene screen to decide how best to treat the patient.

Postdoctoral scholar Izidore Lossos, MD, was the first author on the paper. Other collaborators include Debra Czerwinski, research assistant; Ash Alizadeh, MD, PhD, postdoctoral scholar; Robert Tibshirani, PhD, professor of health research and policy; and David Botstein, PhD, who was professor of biochemistry at Stanford until last year.


Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford. For more information, please visit the Web site of the medical center’s Office of Communication & Public Affairs at http://mednews.stanford.edu.

Amy Adams | EurekAlert!
Further information:
http://mednews.stanford.edu

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>